Literature DB >> 8558021

Isolation and characterization of cell lines with genetically distinct mutations downstream of protein kinase C that result in defective activation-dependent regulation of T cell integrin function.

J L Mobley1, E Ennis, Y Shimizu.   

Abstract

beta 1-integrins expressed on resting T cells support only minimal adhesion to integrin ligands. T cell activation through multiple stimuli, including phorbol ester treatment and Ab cross-linking of the CD3/TCR complex, results in a rapid and transient switch in integrin function from low to high avidity binding. The exact nature of the intracellular signals involved in this avidity switch remain poorly defined, but the ability of phorbol esters to induce such up-regulation implicates a role for protein kinase C (PKC). We have used a genetic approach to identify factors other than PKC that regulate activation-dependent beta 1-integrin function on T cells. We isolated mutants of the Jurkat T cell line that express beta 1- and beta 2-integrins but do not exhibit increased integrin activity in response to PMA stimulation or CD3 cross-linking. PKC activity appears to be normal in the mutants. One mutation is associated with an altered form of the mitogen-activated protein kinase ERK1 and an inability to produce IL-2. Another mutant with defective integrin function has IL-2 production intact. Complementation analysis verified that these two types of mutants are genetically distinct. Thus, two mutations downstream of PKC have been identified that alter the process of integrin regulation without affecting T cell viability or proliferative capacity. These mutants represent novel reagents for the identification of integrin regulatory factors and indicate possible sites of pharmacologic intervention that could prevent integrin-dependent migration and localization in the process of inflammation, while leaving other T cell functions intact.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8558021

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

Review 1.  Regulation of integrin function by T cell activation: points of convergence and divergence.

Authors:  T Zell; W J Kivens; S A Kellermann; Y Shimizu
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

Review 2.  Perspectives series: cell adhesion in vascular biology. Integrin signaling in vascular biology.

Authors:  S J Shattil; M H Ginsberg
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

3.  A genetic analysis of integrin function: Glanzmann thrombasthenia in vitro.

Authors:  E K Baker; E C Tozer; M Pfaff; S J Shattil; J C Loftus; M H Ginsberg
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

4.  Specific activation of leukocyte beta2 integrins lymphocyte function-associated antigen-1 and Mac-1 by chemokines mediated by distinct pathways via the alpha subunit cytoplasmic domains.

Authors:  K S Weber; L B Klickstein; C Weber
Journal:  Mol Biol Cell       Date:  1999-04       Impact factor: 4.138

5.  A novel form of integrin dysfunction involving beta1, beta2, and beta3 integrins.

Authors:  Alison McDowall; David Inwald; Birgit Leitinger; Alison Jones; Ri Liesner; Nigel Klein; Nancy Hogg
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

6.  Subsecond induction of alpha4 integrin clustering by immobilized chemokines stimulates leukocyte tethering and rolling on endothelial vascular cell adhesion molecule 1 under flow conditions.

Authors:  V Grabovsky; S Feigelson; C Chen; D A Bleijs; A Peled; G Cinamon; F Baleux; F Arenzana-Seisdedos; T Lapidot; R R Lobb; R Alon
Journal:  J Exp Med       Date:  2000-08-21       Impact factor: 14.307

7.  Use of a beta1 integrin-deficient human T cell to identify beta1 integrin cytoplasmic domain sequences critical for integrin function.

Authors:  N C Romzek; E S Harris; C L Dell; J Skronek; E Hasse; P J Reynolds; S W Hunt; Y Shimizu
Journal:  Mol Biol Cell       Date:  1998-10       Impact factor: 4.138

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.